JPWO2003080143A1 - Tissue or organ reconstruction substrate containing decellularized tissue matrix and cell growth factor - Google Patents

Abstract

An object of the present invention is to provide a tissue or organ reconstruction base material that has excellent biocompatibility and suppresses graft shrinkage. The present invention relates to a tissue or organ reconstruction substrate comprising a decellularized tissue matrix and a cell growth factor.

Description

TECHNICAL FIELD The present invention relates to a biological tissue or organ reconstruction base material, that is, a regeneration base material that induces cell invasion from surrounding tissues and regenerates and repairs the biological tissue or organ, more specifically, Relates to a substrate for tissue or organ reconstruction comprising a decellularized tissue matrix and a cell growth factor.
BACKGROUND ART Tissue engineering is an attempt to regenerate and repair a damaged or defective part of a living tissue or organ. In this attempt, scaffold materials for the growth and differentiation of various cells have been researched and developed.
So far, scaffolds made of synthetic materials have been made, but there are many problems that need to be improved. Then, preparation of the scaffold material from biological material is considered, and is being tried. To date, attempts have been made to use various biological tissues or organs, decellularize them to suppress immune rejection to tissues or organs, collect only the extracellular matrix, and use it as a scaffold There is. These living body-derived scaffold materials are superior in mechanical properties, body fluid preservation, and the like as compared with synthetic scaffold materials. However, when used in vivo, there is a drawback that the scaffold contracts. There is a method of putting cells as a method for solving this. However, in this method, isolation and seeding of cells are complicated, and another method is desired.
Therefore, we considered adding cell growth factor as a method to suppress the contraction of the scaffold by promoting the invasion of the cell into the scaffold material instead of the cell. This is the point of the present invention. Of course, in some cases, various cells and cell growth factors may be combined and used in a decellularized tissue matrix.
One cause of graft contraction is poor regeneration of tissues or organs such as smooth muscles, and cell growth factors are added, and these factors are gradually released from the decellularized tissue matrix. Or it is thought that regeneration of an organ is promoted.
For example, when considering a bladder reconstruction operation, a bladder enlargement operation is necessary when the bladder is removed due to a congenital disease or due to cancer. Usually, patch repair is performed with the digestive tract, but there are many problems such as urine reabsorption, rupture, and carcinogenesis from the intestinal tract, and regeneration of the bladder itself is ideal.
The history of bladder reconstruction by patch repair using various artificial materials dates back to the 1960s, and a wide variety of materials have been used from animal experiments to clinical trials. However, non-absorbable materials are not suitable for use in the urinary tract due to foreign body reactions, stone formation, etc., while absorbable polymers and various biological materials allow good regeneration on the graft. Therefore, only an insufficient function could be brought about due to the shrinkage of the graft area itself. Since then, there has been progress in bladder reconstruction using the gastrointestinal tract, but as the long-term problems described above become apparent, bladder reconstruction is attracting attention again.
In the 1990s, two biomaterials, small intestine submucosa (SIS) and decellularized bladder matrix (bladder cellular matrix), have been reported to have excellent repairability in animal experiments and new bladder reconstructions have been reported. Although promising as a material, it has been found that none of the repairs of large defects provide sufficient functionality due to the graft shrinkage described above. However, these two biological materials are already in clinical use in the United States for urethral reconstruction, and SIS is in particular distributed as a product of COOK.
On the other hand, another group has reported that graft contraction can be suppressed by seeding autologous bladder cells cultured in large quantities in vitro on the graft and performing bladder repair, and is now in clinical trials. While the usefulness of autologous cell transplantation has been proved by this study, there are many problems that must be cleared before medical care that requires such complicated operations and large medical expenses is widely accepted by the world. .
If it is possible to sufficiently bring out the excellent repair ability of the bladder itself by some method, there is a possibility that it may lead to sufficient bladder regeneration without taking a complicated method such as cell transplantation. Is the current issue.
DISCLOSURE OF THE INVENTION The present invention solves these problems, that is, it can be used not only for reconstruction of the bladder but also various other biological tissues or organs, has excellent biocompatibility, does not cause graft contraction, and is easy to operate. It is an object of the present invention to provide a tissue or organ reconstruction base material that is simple and economical and that draws out tissue repair ability.
As a result of intensive studies to solve the above-mentioned problems, the present inventors have completed the present invention.
The present invention relates to a living tissue or organ having a function of inducing regeneration of a living tissue or organ and regenerating and repairing the living tissue or organ, comprising a decellularized tissue matrix and a cell growth factor It is a base material for reconstruction.
The decellularized tissue matrix in the present invention refers to a material in which most of the cellular components of the biological tissue or organ have been removed and the porous extracellular matrix remains, and decellularized from any biological tissue or organ. Includes all products that have been processed.
The tissue or organ from which the decellularized tissue matrix can be obtained is not particularly limited as long as it is a living tissue or organ. For example, the esophagus, bladder, urethra, small intestine, liver, lung, skeletal muscle, smooth muscle, myocardium , Kidney, bone, cartilage, skin, hair, brain, nerve, muscle, blood vessel, pancreas, retina, cornea, diaphragm, pericardium, serosa, amniotic membrane, tendon, ligament, large intestine, duodenum, trachea, vas deferens, oviduct And ureters and lymphatics. Preferred are the bladder, small intestine and esophagus, and particularly preferred is the bladder.
Cell growth factors in the present invention generally include cell growth factors such as bFGF (basic fibroblast growth factor), aFGF, PDGF, TGF-β1, VEGF, HGF, HB-EGF, CTGF, IGF-I and IGF-II. What is called (cell growth factor), or interleukins, cytokines, physiologically active peptides and chemokines are included, preferably bFGF, HGF, CTGF and PDGF, particularly preferably bFGF. These growth factors can be used alone or in combination of two or more. Specifically, a combination of PDGF / VEGF and bFGF / HGF can be considered.
The bFGF that can be used in the present invention includes those extracted from organs such as the pituitary gland, brain, retina, corpus luteum, and adrenal gland, those produced by genetic engineering techniques such as recombinant DNA technology, and modified products thereof. Including those capable of acting as fibroblast growth factors. Examples of the modified form of bFGF include those in which an amino acid is added, substituted, or deleted in the amino acid sequence of bFGF obtained by the above extraction or genetic engineering technique. The bFGF that can be used in the present invention preferably includes, for example, those described in WO87 / 01728, WO89 / 04832, particularly the former.
The amount of cell growth factor in the tissue or organ reconstruction substrate of the present invention includes the type of decellularized tissue matrix and cell growth factor, the type of tissue or organ to be reconstructed, the lesion site, the extent of the lesion, the patient's condition, etc. For example, it is 1,000 to 100,000 μg, preferably 5,000 to 50,000 μg, and more preferably 2,000 to 30,000 μg in 1 g of decellularized tissue matrix.
The tissue or organ to be reconstructed in the present invention is not particularly limited as long as it is a living tissue or organ. For example, the esophagus, bladder, urethra, small intestine, liver, lung, skeletal muscle, smooth muscle, cardiac muscle, kidney, bone, cartilage , Skin, hair, brain, nerve, muscle, blood vessel, pancreas, retina, cornea, diaphragm, pericardium, serosa, amniotic membrane, tendon, ligament, large intestine, duodenum, trachea, vas deferens, oviduct, ureter and lymphatic vessel Preferred are bladder, small intestine and urethra, and particularly preferred is bladder.
In the tissue or organ reconstruction substrate of the present invention, the tissue or organ for obtaining the decellularized tissue matrix and the tissue or organ to be reconstructed may be the same or different, but both tissues or organs are the same. It may be preferable to be.
BEST MODE FOR CARRYING OUT THE INVENTION The tissue or organ reconstruction substrate of the present invention can be produced by incorporating a cell growth factor into a decellularized tissue matrix.
Decellularized tissue matrix destroys cells from tissues or organs as described above by conventional methods such as treatment with a surfactant such as Triton X-100 or other known treatments such as repeated freeze-thawing and osmotic pressure change. It can be prepared according to the method. The decellularized tissue matrix can be lyophilized and stored for subsequent use.
The method for incorporating the cell growth factor into the decellularized tissue matrix is not particularly limited as long as the cell growth factor can be uniformly distributed in the decellularized tissue matrix. Examples thereof include a method of impregnating a cell growth factor solution and a method of freeze-drying a decellularized tissue matrix and impregnating or adding the cell growth factor solution thereto.
The tissue or organ reconstruction base material of the present invention has a tissue dysfunction due to a congenital disease, when a tissue or organ is excised due to cancer, or when wound healing power is inferior due to complications such as diabetes or When the wound healing power is inferior due to, for example, infection of surrounding tissues, it can be effectively used for reconstruction of the tissues or organs.
The tissue or organ can be reconstructed with the reconstruction base material of the present invention by, for example, using the reconstruction base material as a graft and patch repairing the tissue or organ to be reconstructed.
EXAMPLES Hereinafter, the present invention will be further described with reference to examples, but the present invention is not limited thereto.
Example 1: Preparation of decellularized tissue matrix from rat bladder and its morphological evaluation (method)
The bladder of 250-300 g rat was removed and the surrounding tissue was excised, and then decellularized by the following method.
1) 10 mM PBS + 0.1% sodium azide solution was added and shaken at 37 ° C. for 6 hours.
2) 0.1M PBS was added and washed for several minutes at room temperature.
3) 1M NaCl + 2000 Kunitz units DNase I was added and shaken at 37 ° C. for 6 hours.
4) 4% Triton-X aqueous solution was added and shaken at 37 ° C. for 6 hours.
5) 70% ethanol was added and washed for 1 hour. This was repeated three times.
6) Distilled water was added and washed for 1 hour. This was repeated three times.
The obtained decellularized tissue matrix was fixed with 10% formalin, a HE-stained specimen was prepared, and the morphology was recorded with an optical microscope. Another specimen was fixed with 2.5% glutaraldehyde aqueous solution, dehydrated, substituted with t-butyl alcohol, freeze-dried, coated with platinum deposition, and recorded by observation with a scanning electron microscope.
(Results) As shown in FIGS. 1A and 1B, in the obtained decellularized tissue matrix, most of the cellular components of the bladder were removed, and the porous tissue of the extracellular matrix was removed. Remained.
Example 2: Method for binding cell growth factor by aqueous impregnation of freeze-dried decellularized tissue matrix and evaluation of binding state in aqueous solution (method)
The matrix produced by the above method was frozen in distilled water at −80 ° C. for 12 hours and then freeze-dried for 48 hours using a vacuum pump. This was impregnated with an aqueous bFGF solution and allowed to stand at 37 ° C. for 1 hour to prepare a decellularized tissue matrix containing a cell growth factor. Separately, the matrix before lyophilization was impregnated with an aqueous bFGF solution.
^A 100-200 μM basic fibroblast growth factor (hereinafter abbreviated as bFGF) solution radiolabeled with ¹²⁵ I was impregnated in an amount of 20 μl per rat matrix (dry weight 10-12 mg), (Fig. 2), which was shaken at 37 ° C in 1 ml of PBS or urine, and gamma counter quantified for radioactivity in the solution after a certain period of time, bFGF and matrix Interaction with was evaluated.
(result)
A certain amount of bFGF impregnated in the decellularized tissue matrix was desorbed in the first 24 hours, before and after lyophilization, and thereafter reached a plateau (FIG. 3). Release in the lyophilized matrix was less controlled than when the pre-dried matrix was used. Also, release in urine was even lower than in PBS.
(Discussion)
By this method, a certain amount of bFGF can be attached to the matrix. Moreover, even if this matrix was used for urethral reconstruction, it was not thought to be lost in large quantities in the urine.
Example 3: Evaluation of correlation between decay of cell growth factor in vivo and matrix degradation (method)
In vivo release experiment of bFGF: A matrix containing radiolabeled cell growth factor prepared in the same manner as described above was implanted subcutaneously in the back of 6-week-old female ddY mice. This was sacrificed over time, and the residual radioactivity in the matrix and surrounding tissues was measured to examine the residual bFGF.
Matrix degradation experiment: A decellularized tissue matrix radiolabeled with ¹²⁵ I using a Bolton-Hunter reagent was implanted subcutaneously in mice in the same manner as described above, and the degradation rate in vivo was examined.
(result)
bFGF gradually attenuated over 6 weeks after implantation. In addition, the matrix decomposition took a similar course (FIG. 4).
It is considered that bFGF bound to the decellularized tissue matrix disappears from the living body as the matrix is degraded.
Example 4: Evaluation of survival of cell growth factor activity in vivo (method)
An aqueous solution containing 5 μg of bFGF or 10 μl of PBS was impregnated in 5 mg of a decellularized tissue matrix from rat bladder by the same method as above, and one group was implanted subcutaneously in the mouse by the same method as above, and the remaining two groups Was enclosed in a diffusion chamber and embedded in the mouse subcutaneously in the same manner as described above. After removal after 7 or 14 days, only the matrix was re-implanted subcutaneously in another mouse. In any group, 7 days after matrix implantation (or re-implantation), mice were sacrificed, and 2 cm square subcutaneous tissues around the matrix were collected and evaluated for tissue weight and the like.
(result)
In the matrix impregnated with bFGF, granulation was observed around the matrix for over 2 weeks (FIG. 5).
(Discussion)
It was considered that the activity of bFGF bound to the matrix was maintained even when implanted in vivo.
Example 5: Bladder patch repair operation with decellularized tissue matrix from rat bladder containing bFGF, examination of relationship between bFGF concentration used, bladder reconstructed image on matrix graft, patch size.
(Method)
The rat bladder was decellularized, and the portion corresponding to the top 2/3 of the bladder was taken out therefrom, and decellularized tissue matrices containing various concentrations of bFGF were prepared. Another 10-week-old female Wistar rat was subjected to xylazine-ketamine anesthesia, a midline incision was made in the lower abdomen to expose the bladder, the top side 2/3 of the bladder was excised, and the decellularized tissue matrix as a graft Used to patch repair the missing part.
For the suture between the bladder and the graft, 8-0 absorbent yarn was used, and continuous stitching was performed, and four corners were marked with 7-0 nylon yarn. After completion of the repair, a tube was inserted from the urethra and physiological saline was injected to confirm that there was no leak. At the same time, the graft size at the time of filling was recorded as the major and minor diameters of the marking yarn.
For decellularized tissue matrices containing 0, 5, 25, and 100 μg bFGF, groups of 9 animals were made each, 4 animals were evaluated 4 weeks after surgery and 5 animals were evaluated at 12 weeks. Each was made into A, B, C, D group. In addition, as a control, 6 groups were produced that were sutured and closed after excision of 2/3 bladder, and 3 animals were evaluated after 4 and 12 weeks.
The lower abdomen was incised under urethane (900 mg / kg, sc) anesthesia to expose the bladder, and a 3 Fr polyethylene tube was placed from the urethra. A T-tube was connected to the end of the tube, one connected to the pressure transducer and the other to the infusion pump. Excise the bladder from the wound and make it empty, then inject physiological saline from the infusion route at a rate of 6.0 ml / hr to measure the intravesical pressure, and leak the infusate around the urethral placement tube to maximize the bladder capacity It was. The test was performed 5 times for each individual, and the average value of 3 intermediate values was taken as the bladder capacity of the individual.
After completion of the test, the rats were sacrificed and the bladder was emptied. Then, 10% formalin or Krebs solution equivalent to the bladder volume was injected, the external urethral orifice was clamped, and the distance between the marking threads was measured. The graft area was defined as major axis × minor axis / 2.
In each group, all the animals in the 4th week and 3 animals in the 12th week were fixed with formalin, and then photographs were taken, followed by dehydration, paraffin embedding, and HE staining.
(result)
At 4 weeks, epithelial regeneration was complete in all groups. In the submucosa, the higher the concentration of bFGF, the greater the amount of mesenchymal cells that infiltrated into the graft (FIGS. 6-7). At this time, the shrinkage of the graft area was suppressed depending on the concentration of bFGF (FIG. 8).
At the 12th week, smooth muscle layer formation was observed in each group (FIG. 9).
EFFECT OF THE INVENTION The tissue or organ reconstruction substrate of the present invention can be used in tissue or organ reconstruction such as patch reconstruction for bladder reconstruction, has excellent biocompatibility, does not cause graft repair, and is simple and economical. Tissue repair ability can be brought out by an inexpensive method.
The tissue or organ reconstruction base material of the present invention has the effect of suppressing graft shrinkage that cannot be obtained with conventional living body-derived scaffold materials by gradual release of cell growth factors and promotion of cell invasion from the tissue to the base material. Have Moreover, the method of the present invention is superior to the conventional method of placing cells in a living body-derived scaffold material.
[Brief description of the drawings]
FIG. 1 is a diagram of a decellularized tissue matrix from rat bladder (A) and its HE staining result (B).
FIG. 2 shows the preparation of a decellularized tissue matrix from the rat bladder and the step of containing the cell growth factor in the rat bladder before decellularization treatment (1), the decellularized tissue matrix from the rat bladder (2 ), A decellularized tissue matrix (3) after lyophilization, and a decellularized tissue matrix (4) after impregnation in a cell growth factor aqueous solution.
FIG. 3 is a graph showing the release of cell growth factor from a decellularized tissue matrix containing cell growth factor in aqueous solution (PBS).
FIG. 4 is a graph showing degradation of decellularized tissue matrix and attenuation of cell growth factor contained in the decellularized tissue matrix under the subcutaneous condition of mice.
FIG. 5 shows a graph (upper part) and a macroscopic image showing the granulation ability of a decellularized tissue matrix containing a cell growth factor implanted in a living body for a certain period of time on the 7th day after re-implantation into a mouse. It is a figure (lower part).
FIG. 6 shows the results of HE staining of bladder tissue on the grafts of rats of Group A, Group B, Group C and Group D 4 weeks after surgery ((A), (B), (C) and (D, respectively). )).
FIG. 7 shows the urinary bladders of the rats of Group A, Group B, Group C, and Group D 4 weeks after the operation ((A), (B), (C), and (D), respectively). A region surrounded by an arrow is a graft site.
FIG. 8 is a graph showing the graft areas of rats in Group A, Group B, Group C, and Group D 4 weeks after surgery.
FIG. 9 shows the results of HE staining of bladder tissue on the grafts of rats of Group A, Group B, Group C and Group D 12 weeks after surgery ((A), (B), (C) and (D, respectively). )).

Claims (4)

A base material for tissue or organ reconstruction comprising a decellularized tissue matrix and a cell growth factor. The reconstruction substrate according to claim 1, wherein the cell growth factor is bFGF. The reconstruction base material according to claim 1 or 2, wherein the decellularized tissue matrix is derived from a bladder. A method for producing a reconstruction base material according to any one of claims 1 to 3, comprising impregnating or adding a cell growth factor solution to a decellularized tissue matrix.

Images